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Abstract 
Background: To evaluate the influence of the progonistic nutritional index (PNI) and weight loss on metastasis and 
long‑term mortality in nasopharyngeal carcinoma (NPC).
Methods: We retrospectively reviewed 694 newly diagnosed patients with non‑disseminated, biopsy‑proven NPC. 
Survival analysis was used to evaluate the predictive value of PNI and weight loss.
Results: Multivariate analysis demonstrated that a low pre‑therapy PNI (< 55.0) was an independent predictor of 
poor overall survival (OS) (P = 0.012), distant metastasis‑free survival (DMFS) (P = 0.011) and progression‑free survival 
(P = 0.012). High weight loss (HWL, weight loss during treatment ≥10 %) was an independent predictor of poor OS 
(P = 0.001) and DMFS (P = 0.014). Advanced stage disease, female gender, chemotherapy, high white blood cell 
count, high serum globulin concentration and pre‑therapy body‑mass index were predictors of HWL.
Conclusion: Pre‑therapy PNI and weight loss have significant predictive value for metastasis and mortality in patients 
with NPC.
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inflammation response
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Background
Nasopharyngeal carcinoma (NPC) is one of the most 
commonly diagnosed malignancies in Southeast Asia, 
with an annual incidence of 30–80 per 10,000 popula-
tions [1]. Radiotherapy (RT), alone or in combination 
with chemotherapy, is the mainstay treatment for NPC 
[2]. Advances in diagnostic imaging, radiotherapeutic 
techniques and chemotherapy regimens have provided 
significant survival benefits for locally advanced NPC 
[3]. However, 20 % of the patients with advanced disease 
still develop metastases even after they are found to be 
disease free [2]. Metastatic NPC is associated with poor 
prognosis, with a median survival period of approxi-
mately 17 months [4]. Identifying the factors that predict 
the aggressiveness of NPC and the associated mortality is 
of utmost importance.
Variations in the outcomes of cancer patients are not 
solely determined by the characteristics of the tumour 
but also by the host response factors [5, 6]. The sys-
temic inflammatory response is a non-specific response 
secondary to tumour necrosis or local tissue damage 
caused by tumour-host cell interactions [7]. As part of 
the systemic inflammatory response, pro-inflamma-
tory cytokines and growth factors are released, some of 
which cause metabolic disturbances and the loss of lean 
tissue and promote tumour growth [8]. Recently, there 
has been increasing evidence to suggest that systemic 
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inflammatory response is of prognostic value in patients 
with various types of cancers: it can predict survival, 
independent of the disease stage, in advanced cancers 
[5, 7]. The host systemic inflammatory response can be 
assessed by examining changes in the circulating concen-
trations of acute-phase proteins and other cellular com-
ponents, such as neutrophils, lymphocytes, monocytes 
and platelets [9].
The prognostic nutritional index (PNI), which reflects 
the albumin concentration and lymphocyte count, is a 
novel systemic inflammation-based prognostic score [9]. 
It was first introduced by Onodera et  al. to assess the 
immunological and nutritional status of patients under-
going gastrointestinal surgery [10]. Research conducted 
over the last decade or so has demonstrated associations 
between a low PNI and poor survival in several types of 
cancers [11–18]. The impact of PNI on metastasis and 
mortality in NPC has not yet been addressed.
Weight loss is commonly observed in cancer patients 
and is associated with increased morbidity and mortality. 
The prevalence of weight loss is estimated to be between 
40 and 80 %, with a particularly high incidence in patients 
with head and neck cancer [6]. Significant weight loss 
occurs frequently during radiotherapy in NPC patients 
[20–22]; it increases the risk of treatment gaps [23] and 
is associated with poor survival [24]. Accumulative data 
have demonstrated that weight loss is not just a nutri-
tional indicator that reflects reduced intake or nutri-
tional imbalance. The presence of systemic inflammatory 
response has recently been shown to be associated with 
weight loss in cancer patients [5]. Unlike other prognos-
tic factors, weight loss can be treated as a therapeutic 
target that can be managed through available nutritional 
support. Based on the fact that early nutritional man-
agement is associated with better prognosis in head and 
neck cancer [25], the identification of risk factors for 
weight loss, particularly pre-therapy risk factors, is of 
great importance for early intervention. In this study, 
we re-examined weight loss in NPC and its effect on the 
clinical outcome, given the recent advances in the treat-
ment of NPC.
The aims of the present study were (1) to evaluate the 
predictive value of PNI, weight loss and other selective 
markers of systemic inflammatory response for survival, 
and (2) to determine whether certain pre-therapy clini-




We conducted a retrospective study using the in-patient 
medical records of all newly diagnosed patients with his-
tologically proven, non-disseminated NPC treated at Sun 
Yat-sen University Cancer Center (Guangzhou, China) 
between January 2003 and December 2006. In all, 719 
cases were evaluated, among which 25 (3.5 %) were sub-
sequently eliminated, including 18 (2.5  %) patients with 
incomplete laboratory data, 5 (0.7  %) who were unable 
to complete the prescribed treatment, and 2 (0.3  %) 
with other malignancies in addition to NPC. Thus, 694 
patients were finally included in the analysis. The study 
was approved by the Institutional Review Board of Sun 
Yat-sen University Cancer Center. As this was a retro-
spective analysis of routine data, we requested and were 
granted a waiver of individual informed consent from 
the ethics committee. Patient records/information was 
anonymized and de-identified prior to analysis.
Treatment
All the patients underwent a pretreatment baseline eval-
uation including complete medical history, physical and 
neurological examinations, hematology and biochemistry 
profiles, MRI scan of the neck and nasopharynx, chest 
radiography, and abdominal sonography. The treatment 
plans were determined according to standard protocols 
depending on the tumor stage and general health of the 
patient. All the patients were treated with continuous 
definitive radiotherapy with daily fractions of 2.0 Gy five 
times per week using a linear accelerator (6–8 MV). The 
radiation dose ranges in the nasopharynx, lymph node-
positive area and lymph node-negative area were 60–80, 
60–70 and 50–60  Gy, respectively. In total, 302/694 
(43.5 %) patients received precise radiotherapy, of whom 
279 (40.2  %) received intensity-modulated radiotherapy 
and 23 (3.3 %) received 3-dimensional conformal radio-
therapy. Induction or adjuvant chemotherapy consisted 
of three cycles of cisplatin with 5-fluorouracil, or cisplatin 
with taxanes every 3  weeks. Concurrent chemotherapy 
consisted of cisplatin every 3  weeks or cisplatin weekly. 
In total, 479/694 (69.0 %) patients underwent chemother-
apy. Most of them (376/479, 78.5 %) had advanced stage 
disease (classified as T3–T4 and/or N2–N3). When pos-
sible, salvage treatments (including afterloading, surgery, 
and chemotherapy) were provided for residual disease or 
disease relapse. Participants were on 100  % oral intake 
at the time of the study, and no patient used any form of 
enteral tube feeding or total parenteral nutrition. The diet 
of the patients was not monitored in any way and was 
based on their choice, motivation, and ability.
Data collection
Data were gathered from medical records, including 
age; sex; body weight and height; pre-therapy laboratory 
counts of white cells, neutrophils, lymphocytes, hemo-
globin and platelets; bilirubin, alkaline phosphatase, 
albumin and globulin concentration; pathological types; 
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clinical stage; and type of treatment. The neutrophil-to-
lymphocyte ratio (NLR) was calculated by dividing the 
neutrophil count by the lymphocyte count. The plate-
let-to-lymphocyte ratio (PLR) was calculated by divid-
ing the platelet count by the lymphocyte count. PNI was 
calculated using the following formula: serum albumin 
(g/L) +  0.005 ×  total lymphocyte count/μL [9]. Weight 
loss during treatment was calculated as follows: (weight 
at the baseline visit) −  (weight at the end of treatment). 
The end of treatment was defined as completion of the 
entire prescribed treatment plan, for example, the end 
of adjuvant chemotherapy for concurrent chemo-RT 
plus adjuvant chemotherapy. Three groups were defined 
according to the percentage of weight loss: <5  % =  low 
weight loss (LWL); 5–10  %  =  moderate weight loss 
(MWL); and ≥10  %  =  high weight loss (HWL). The 
patients were also classified into four groups according to 
their pre-therapy body mass index (BMI, kg/m2) accord-
ing to the WHO recommendations for Asian popula-
tions [26]: <18.5  kg/m2  =  underweight; 18.5–22.99  kg/
m2  =  normal weight; 23.0–27.49  kg/m2  =  overweight, 
and ≥ 27.5 kg/m2 = obese.
Follow‑up
After completion of the therapy, the patients were exam-
ined every 3  months during the first 2  years, and every 
5 months thereafter for up to 6 years or until death. The 
end of the follow-up was February 28, 2013. The median 
follow-up period was 88 months (range 5–123 months). 
None of the patients were lost to follow-up. The follow-
ing end points (time to the first defining event) were 
assessed: distant metastasis-free survival (DMFS), overall 
survival (OS), progression-free survival (PFS) and local 
relapse-free survival (LRFS).
Statistical analysis
All the calculations were performed using the Statistical 
Package for the Social Sciences, version 20.0 (SPSS, Chi-
cago, IL, USA). Circulating marker levels were analysed 
as binary variables by using the median values of each 
marker as the cut-off levels, which is more than or equal 
to the median in the group with high values and less than 
the median in the group with low values. Pearson Chi-
square (χ2) tests or Fisher’s exact test (when the expected 
number per cell was <5) was used to analyze categorical 
variables. Survival curves were drawn using the Kaplan–
Meier method and compared using the log-rank test. 
Multivariate analysis using a Cox proportional hazards 
model was used to test independent significance by back-
ward elimination of insignificant explanatory variables. 
For each categorical predictor, the reference category 
was defined as the category with the best prognosis: for 
example, LWL was the weight loss reference category. 
Two-tailed P values <0.05 were considered to indicate 
significance.
Results
Clinicopathological features and treatment outcomes
The clinicopathological characteristics of the 694 
patients, including 517 (74.5  %) males and 177 (25.5  %) 
females, are presented in Table  1. The median age at 
diagnosis was 44  years (range 13–78  years). Based on 
the WHO criteria, 99.3 % of the patients had type II or 
III disease and 0.7 % had type I disease. All the patients 
were staged according to the 7th edition of the Interna-
tional Union against Cancer/American Joint Committee 
on Cancer (UICC/AJCC) staging system for NPC [27].
The median PNI in our patient population was 55.0 
(range 39.6–80.3). The median weight loss during treat-
ment was 4.5 kg (range −2.0 to 16.0 kg), and the median 
percentage weight loss was 6.7 % (range −4.0 to 22.5 %). 
Additionally, 26.9  % of the patients experienced ≥10  % 
weight loss.
At the last follow-up, 185/694 patients (26.7  %) had 
tumor progression after the treatment, including 70 
(10.1 %) patients who developed local or regional recur-
rence and 130 (18.7  %) who developed distant metasta-
sis. By the end of the follow-up, 164/694 patients (23.6 %) 
died, including 150 (21.6  %) who died of NPC and 14 
(2.0  %) who died of other causes. The 5-year OS, PFS, 
DMFS and LRFS rates were 82.6, 76.2, 83.6 and 89.9 %, 
respectively.
Prognostic value of PNI and weight loss
Univariate analysis identified pre-therapy PNI as a sig-
nificant predictive factor for DMFS (P  =  0.002), OS 
(P = 0.004) and PFS (P = 0.006). Weight loss was signifi-
cantly associated with poor DMFS (P = 0.006) as well as 
OS (P < 0.001), and had a marginally significant influence 
on PFS (P = 0.063). However, both pre-therapy PNI and 
weight loss had no predictive value for LRFS (P = 0.281; 
P  =  0.297). The Kaplan–Meier curves are shown in 
Figs. 1 and 2.
Multivariate analysis for DMFS, OS and PFS was per-
formed to adjust for various prognostic factors. The fol-
lowing parameters were included in the Cox proportional 
hazards model: age (≥50 vs. <50 years), gender (male vs. 
female), T classification (T3–4 vs. T1–2), N classification 
(N1–3 vs. N0), chemotherapy (yes vs. no), pre-therapy 
BMI, pre-therapy white blood cell count (≥6.9 vs. <6.9 k/
μL), pre-therapy NLR (≥2.3 vs. <2.3), pre-therapy PLR 
(≥120.7 vs. <120.7), pre-therapy blood platelet count 
(≥221 vs. <221 k/μL), pre-therapy hemoglobin (<144 vs. 
≥144  g/L), pre-therapy PNI (<55.0 vs. ≥55.0), pre-ther-
apy alkaline phosphatase (≥68 vs. <68  U/L), pre-ther-
apy bilirubin (≥4.1 vs. <4.1 μmol/L), pre-therapy serum 
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Table 1 Characteristics of the 694 patients with NPC
Variable No. (%) LWL/MWL (weight  
loss <10 %)




 <50 473 (68.2) 350 (74.0) 123 (26.0)
 ≥50 221 (31.8) 157 (71.0) 64 (29.0)
Sex 0.001
 Male 517 (74.5) 394 (76.2) 123 (23.8)
 Female 177 (25.5) 113 (63.8) 64 (36.2)
T classification 0.001
 T1–2 313 (45.1) 248 (79.2) 65 (20.8)
 T3–4 381 (54.9) 259 (68.0) 122 (32.0)
N classification 0.009
 N0 196 (28.2) 157 (80.1) 39 (19.9)
 N1–3 498 (71.8) 350 (70.3) 148 (29.7)
Clinical stage <0.001
 I + II 235 (33.9) 191 (81.3) 44 (18.7)
 III + IV 459 (66.1) 316 (68.8) 143 (31.2)
Chemotherapy <0.001
 No 215 (31.0) 186 (86.5) 29 (13.5)
 Yes 479 (69.0) 321 (67.0) 158 (33.0)
White blood cell count, k/μL 0.035
 <6.9 339 (48.8) 260 (76.7) 79 (23.3)
 ≥6.9 355 (51.2) 247 (69.6) 108 (30.4)
NLR 0.171
 <2.3 360 (51.9) 271 (75.3) 89 (24.7)
 ≥2.3 334 (48.1) 236 (70.7) 98 (29.3)
Blood platelet count, k/μL 0.221
 <221 342 (49.3) 257 (75.1) 85 (24.9)
 ≥221 352 (50.7) 250 (71.0) 102 (29.0)
PLR 0.347
 <120.7 347 (50.0) 259 (74.6) 88 (25.4)
 ≥120.7 347 (50.0) 248 (71.5) 99 (28.5)
Hemoglobin, g/L 0.283
 <144 335 (48.3) 251 (74.9) 84 (25.1)
 ≥144 359 (51.7) 256 (71.3) 103 (28.7)
PNI 0.301
 <55.0 345 (49.7) 246 (71.3) 99 (28.7)
 ≥55.0 349 (50.3) 261 (74.8) 88 (25.2)
Alkaline phosphatase, U/L 0.337
 <68 340 (49.0) 254 (74.7) 86 (25.3)
 ≥68 354 (51.0) 253 (71.5) 101 (28.5)
Bilirubin, μmol/L 0.859
 <4.1 345 (49.7) 251 (72.8) 94 (27.1)
 ≥4.1 349 (50.3) 256 (73.4) 93 (26.6)
Albumin, g/L 0.399
 <45.4 338 (48.7) 242 (71.6) 96 (28.4)
 ≥45.4 356 (51.3) 265 (74.4) 91 (25.6)
Globulin, g/L 0.009
 <30.2 339 (48.8) 263 (77.6) 76 (22.4)
 ≥30.2 355 (51.2) 244 (68.7) 111 (31.3)
Body mass index, kg/m2 0.040
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globulin concentration (≥30.2 vs.<30.2 g/L), and the per-
centage weight loss groups. The serum albumin concen-
tration was excluded, as it was used in the calculation of 
PNI.
Consistent with the results of the univariate analy-
sis, pre-therapy PNI was found to be an independent 
predictive factor for DMFS, OS and PFS (P  =  0.011, 
0.012 and 0.012, respectively). As weight loss increased, 
the risk of metastasis and death increased (P  =  0.038 
and 0.002 for DMFS and OS, respectively). Compared 
to LWL, HWL had a strong adverse effect on DMFS 
and OS (P  =  0.014; P  =  0.001). Being underweight at 
the baseline was significantly associated with DMFS 
(P  =  0.008), compared to having normal weight. 
Besides, the serum alkaline phosphatase concentration 
was significantly associated with DMFS, OS and PFS. 
The serum globulin concentration was a significant 
prognostic factor for DMFS and OS. T classification was 
identified as an independent predictive factor for PFS. 
Furthermore, N classification was identified as an inde-
pendent predictive factor for PFS and DMFS. In con-
trast, age, gender, chemotherapy, white blood cell count, 
NLR, PLR, hemoglobin, blood platelet count and bili-
rubin were not independent predictive factors for any 
survival endpoint according to the results of the multi-
variate analysis (Table 2).
Table 1 continued
Variable No. (%) LWL/MWL (weight  
loss <10 %)
HWL (weight  
loss ≥10 %)
P value
 Underweight (<18.5) 66 (9.5) 57 (86.4) 9 (13.6)
 Normal weight (18.5–22.99) 305 (43.9) 225 (73.5) 80 (26.2)
 Overweight (23.0–27.49) 273 (39.3) 192 (70.3) 81 (29.7)
 Obese (≥27.5) 50 (7.3) 33 (66.0) 17 (34.0)
NLR neutrophil/lymphocyte ratio, PLR platelet/lymphocyte ratio, PNI prognostic nutritional index, LWL low weight loss, MWL moderate weight loss, HWL high weight 
loss
Fig. 1 Weight loss related outcomes. Kaplan–Meier overall survival curves (a), progression‑free survival curves (b), distant metastasis‑free survival 
curves (c) and local relapse‑free survival curves (d) for patients with NPC stratified by weight loss during treatment into low weight loss (LWL), mod‑
erate weight loss (MWL) and high weight loss (HWL) groups
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Association of weight loss with pre‑therapy clinical 
features
The distribution of percentage weight loss differed sig-
nificantly when the patients were stratified by T clas-
sification, N classification and clinical stage. The HWL 
group contained a significantly higher number of patients 
with T3-4 and N1-3 stage disease than those with T1-2 
(P = 0.001) and N0 (P = 0.009) stage disease. Moreover, 
44/235 (18.7 %) and 143/459 (31.2 %) of the patients with 
stage I + II and stage III + IV disease respectively expe-
rienced more than 10  % weight loss during treatment 
(P < 0.001). Female patients and patients who underwent 
chemotherapy had higher weight loss during treatment 
than male patients (P = 0.001) and patients who did not 
undergo chemotherapy (P  <  0.001). Additionally, the 
HWL group contained a significantly higher number of 
patients with a high pre-therapy white blood cell count 
and high pre-therapy serum globulin concentration than 
patients with a low white blood cell count (P  =  0.035) 
and low serum globulin concentration (P = 0.009). More-
over, the proportion of patients in the HWL group signif-
icantly increased along with the increase in pre-therapy 
BMI (Table 1).
Discussion
The findings in this study indicate that PNI and weight 
loss are associated with tumor progression, metastasis 
and long-term mortality in patients with NPC. Moreo-
ver, higher pre-therapy BMI, white blood cell count, 
serum globulin level, female gender, chemotherapy, and 
advanced stage disease were predictive of greater weight 
loss during treatment.
PNI is calculated from albumin concentration and lym-
phocyte count. Serum albumin is known to correlate with 
systemic inflammation through high levels of pro-inflam-
matory cytokines. Albumin may help to stabilize cell 
growth and DNA replication, buffer a variety of biochem-
ical changes, and maintain sex hormone homeostasis to 
protect against cancers [28]. Growing numbers of stud-
ies have demonstrated associations between a low serum 
albumin level and an increased severity of disease, a high 
risk of disease progression and poor survival in cancer 
patients [28]. Lymphocytes are crucial components of 
adaptive immune system, which is always suppressed in 
tumours through several pathways, including inhibition 
of dendritic cell differentiation and activation, infiltration 
of regulatory T cells and tumour-associated macrophages 
Fig. 2 Prognostic nutritional index related outcomes. Kaplan–Meier overall survival curves (a), progression‑free survival curves (b), distant metasta‑
sis‑free survival curves (c) and local relapse‑free survival curves (d) for patients with NPC stratified by prognostic nutritional index (PNI)
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[7, 8, 29]. Infiltrating lymphocytes have been reported 
to represent an effective antitumour cellular immune 
response. A low peripheral lymphocyte level may indi-
cate a poor lymphocyte-mediated immune response to 
tumour and suggest a poor prognosis [29]. Previous stud-
ies have shown that a high lymphocyte count was associ-
ated with improved clinical outcome in rectal cancer [30] 
and pancreatic ductal adenocarcinoma [31]. High periph-
eral lymphocyte percentage was also demonstrated to be 
associated with a long survival of patients with NPC [29].
Consistent with our results for NPC, the prognostic 
value of PNI has been validated in other tumors in sev-
eral published studies, including pancreatic cancer [11], 
gastric carcinoma, esophageal carcinoma [13], malignant 
pleural mesothelioma [14], hepatocellular carcinoma [15, 
16], colorectal cancer [17], and renal cell cancer [18]. To 
the best of our knowledge, this is the first study to spe-
cifically focus on the predictive value of PNI in NPC. In 
the present study, it would appear that PNI is superior to 
other systemic inflammation-based factors, in particular, 
the white blood cell count, NLR and PLR, in predicting 
survival in NPC.
Another prognostic factor for metastasis and mortality 
in NPC that we identified in this study is serum globu-
lin. High levels of globulins are attributable to increased 
accumulation of acute-phase proteins and immuno-
globulins, as well as other serum proteins, and all these 
changes are reflective of an inflammatory state. Besides, 
elevated levels of serum alkaline phosphatase have been 
reported to predict disease progression and poor out-
come in some malignancies, including NPC [19]. It was 
considered as an indicator of distant micrometastases in 
other organs such as bone [19].
Another factor that this study examined was weight 
loss, which has been shown to affect the clinical outcome 
in NPC patients. Ng et  al. reported that the mean per-
centage weight loss during radiotherapy in 38 patients 
with NPC from Hong Kong was 10.8 %, and that 55 % of 
the patients experienced ≥10  % weight loss by the end 
of the treatment [20]. Qiu et al. conducted a prospective 
study of 159 patients with NPC and observed a median 
weight loss of 6.9 kg (range 2.1–12.6 kg) [21]. Oates et al. 
reported that the median weight loss during concur-
rent chemoradiotherapy in 14 patients with NPC was 
Table 2 Multivariate analysis of prognostic factors in the patients with nasopharyngeal carcinoma (N = 694)
NLR neutrophil/lymphocyte ratio, PLR platelet/lymphocyte ratio, PNI prognostic nutritional index, LWL low weight loss, MWL moderate weight loss, HWL high weight 
loss, OS overall survival, OS overall survival, PFS progression-free survival, DMFS distant metastasis-free survival, 95 % CI 95 % confidence interval, HR hazard ratio
Variable DMFS OS PFS
P value HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI)
Age (≥50 vs. <50 years)
Sex (male vs. female)
T classification (T3–4 vs. T1–2) 0.051 1.392 (0.998–1.942) 0.028 1.410 (1.038–1.915)
N classification (N1–3 vs. N0) 0.005 1.903 (1.215–2.982) 0.054 1.439 (0.994–2.085) 0.005 1.663 (1.165–2.374)
Chemotherapy (yes vs. no)
White blood cell count (≥6.9 vs. <6.9 k/μL)
NLR (≥2.3 vs. <2.3)
Blood platelet count (≥221 vs. <221 k/μL) 0.078 1.373 (0.965–1.954)
PLR (≥120.7 vs. <120.7)
Hemoglobin (<144 vs. ≥144 g/L)
PNI (<55.0 vs. ≥55.0) 0.011 1.603 (1.116–2.303) 0.012 1.501 (1.095–2.058) 0.012 1.460 (1.088–1.961)
Alkaline phosphatase (≥68 vs. <68 U/L) 0.002 1.773 (1.233–2.549) 0.003 1.626 (1.177–2.247) <0.001 1.711 (1.266–2.313)
Bilirubin (≥4.1 vs. <4.1 μmol/L)
Globulin (≥30.2 vs. <30.2 g/L) 0.032 1.485 (1.034–2.134) 0.041 1.396 (1.013–1.924)
Body mass index 0.017
 Underweight (<18.5 kg/m2) 0.008 2.060 (1.212–3.501)
 Normal weight (18.5–22.99 kg/m2) 1
 Overweight (23.0–27.49 kg/m2) 0.297 1.230 (0.834–1.812)
 Obese (≥27.5 kg/m2) 0.185 0.534 (0.211–1.351)
Weight loss, % 0.038 0.002
 LWL (less than 5.0 %) 1 1
 MWL (5.0–9.99 %) 0.343 1.243 (0.792–1.950) 0.082 1.437 (0.955–2.161)
 HWL (10 % or more) 0.014 1.787 (1.127–2.834) 0.001 2.053 (1.362–3.095)
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8.2 kg (range 2.3–13.9 kg), which represented a percent-
age weight loss range of 4–17 % [22]. Further, Shen et al. 
conducted a retrospective study in 2433 NPC patients 
and reported that high weight loss during radiotherapy 
(weight loss ≥5  %) was indepentently associated with 
poor survival [24]. In the present study, we evaluated 
weight loss during the entire treatment procedure and 
found that high weight loss (weight loss ≥10 %) was still a 
predictor of metastasis and survival.
We speculate that there are three possible reasons 
why weight loss significantly associates with mortality. 
First, percentage weight loss is a commonly used tool in 
assessment of recently developed malnutrition. Malnu-
trition can weaken a number of human defense mecha-
nisms, including anatomic barriers, cellular and humoral 
immunity, and phagocyte function [5–7], thus promoting 
susceptibility to infection and further compromising the 
response to malignancy. Second, weight loss may cause 
treatment interruption and decrease treatment tolerance, 
thus affecting therapeutic efficacy [23]. Additionally, 
weight loss is also an indicator of systemic inflammatory 
response, that encompasses a variety of physiologic alter-
ations facilitating tumour development, invasion, and 
metastasis [5, 8].
Weight loss during NPC treatment is partially due to 
oral mucositis induced by radiotherapy and chemother-
apy. Oral mucositis is considered to be the most impor-
tant acute side effect in almost all patients undergoing 
radiotherapy of the head and neck [32]. The oral lesions 
may cause dysphagia with solid and liquid food, dysar-
thria and odynophagia, and thus directly reduce food 
intake. Effective management of oral mucositis may mini-
mize the symptoms, improve the nutritional status, allow 
for more effective cancer treatment and improve patient 
survival [32].
Many factors affect weight loss in cancer patients. Con-
sistent with the findings of Qiu et  al. [21], we observed 
that high weight loss was associated with heavier tumor 
burden and chemotherapy. Patients treated with chemo-
therapy are more likely to have advanced stage disease. 
Despite the encouraging results achieved by multimodal 
therapy in terms of tumor control, aggressive chemo-
radiotherapy can lead to more serious acute toxicities, 
which directly impact the ability to eat [32]. We also 
found that female patients were more likely to experience 
high weight loss than males. Similar findings have been 
reported in head and neck cancer [33]. Further, a recent 
study showed that female patients with NPC tended to 
experience anxiety before treatment, lacked a positive 
coping mode, and experienced poor quality of life after 
radiotherapy [34]. We speculated that poorer treatment 
compliance and tolerance among female patients may 
account for their greater weight loss. In the present study, 
higher pre-therapy BMI was associated with higher 
weight loss in NPC, which has also been reported by 
Qiu et al. [21]. A patient with a higher pre-therapy BMI 
might have more weight to lose and show strong resist-
ance to malnutrition. Furthermore, a high white blood 
cell count and high serum globulin concentration were 
shown to be predictors of high weight loss. In keeping 
with our results, there is good consistent evidence that 
the presence of systemic inflammatory response is asso-
ciated with increased weight loss, elevated resting energy 
expenditure, loss of lean tissue and functional decline 
[5]. These findings may suggest the effectiveness of anti-
inflammatory therapy in weight loss in cancer patients.
There are some limitations to the current study. First, 
the data were retrospectively analyzed. Second, PNI was 
only assessed at a single time point before the treatment. 
Thus, the relationship between the kinetics of PNI and its 
prognostic effect in NPC would be of considerable inter-
est. Third, there were no standard criteria for nutritional 
support in patients undergoing oncotherapy during the 
time period of the study. Therefore, insufficient infor-
mation on food intake and nutritional status during the 
treatment is available for further analysis of weight loss.
Conclusion
The pre-therapy PNI and weight loss represent important 
prognostic factors for evaluating the long-term metasta-
sis and mortality in patients with NPC. This study offers 
good insight into the relationship between the systemic 
inflammatory response and survival in patients with 
NPC. The results would also be highly useful with regard 
to selecting patients for preventive measures before 
treatment.
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